Pluri Inc. (NASDAQ:PLUR – Get Free Report) was the recipient of a significant drop in short interest in October. As of October 15th, there was short interest totalling 2,300 shares, a drop of 62.3% from the September 30th total of 6,100 shares. Based on an average daily trading volume, of 11,500 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the shares of the stock are sold short.
Pluri Price Performance
Shares of PLUR stock opened at $4.32 on Friday. The company has a debt-to-equity ratio of 4.44, a current ratio of 6.98 and a quick ratio of 6.98. The firm’s 50-day moving average is $5.25 and its two-hundred day moving average is $5.50. Pluri has a 12 month low of $3.45 and a 12 month high of $8.48. The company has a market capitalization of $23.63 million, a PE ratio of -0.73 and a beta of 1.60.
Pluri (NASDAQ:PLUR – Get Free Report) last issued its earnings results on Wednesday, September 18th. The company reported ($2.98) EPS for the quarter. The firm had revenue of $0.26 million for the quarter. Pluri had a negative return on equity of 493.74% and a negative net margin of 6,341.03%.
Pluri Company Profile
Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.
Featured Articles
- Five stocks we like better than Pluri
- Top Biotech Stocks: Exploring Innovation Opportunities
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is a Death Cross in Stocks?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for Pluri Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluri and related companies with MarketBeat.com's FREE daily email newsletter.